From Iran To The US: From Scientist To Entrepreneur
Interview With Bioniz CEO Nazli Azimi
California-based Bioniz’s lead candidate for cutaneous T-cell lymphoma has been granted orphan drug designation and expects to begin Phase III trials in the second half of 2021. CEO Nazli Azimi explains the science, which originated from her research in academia, and talks about her entrepreneurial journey.
You may also be interested in...
A selection of articles you might have missed from July 2021, including exclusive interviews with industry leaders and a deep dive into the RNA therapy pipeline.
With digital therapies and devices seeing widespread adoption in response to lockdown limitations during the COVID-19 pandemic, Kaiku Health is in a strong position to expand its patient monitoring software. CEO Lauri Sippola spoke with In Vivo about the platform and the company’s plans for 2021 and beyond.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.